From The Conversation · Ziyad Al-Aly · · 1m 30s
GLP-1 Drugs Carry Eye Risk Warning
FDA warns GLP-1 drugs may cause rare vision loss condition.
In brief
FDA warns GLP-1 drugs may cause rare vision loss condition. FDA adds NAION risk to GLP-1 drug warnings after studies show 2.6 extra cases per 100,000 users. Originally reported by The Conversation.
Quick answers
- What is NAION?
- NAION is an injury to the optic nerve caused by sudden blood flow reduction, leading to sudden vision loss or blindness.
- What is the key takeaway from GLP-1 Drugs Carry Eye Risk Warning?
- FDA adds NAION risk to GLP-1 drug warnings after studies show 2.6 extra cases per 100,000 users.
FDA warns GLP-1 drugs

The U.S. Food and Drug Administration announced on Nov. 9, 2026 that GLP-1 drugs carry a warning label for a rare eye condition that can cause vision loss.
What is NAION?
NAION is an injury to the optic nerve caused by sudden blood flow reduction, leading to sudden vision loss or blindness.
How the link was found
A 2024 study of 17,000 patients showed increased NAION risk among GLP-1 users, with 2.6 extra cases per 100,000 patients on GLP-1 drugs.
FDA's risk analysis

Per year, GLP-1 drugs cause 6.4 NAION cases per 100,000 patients versus 3.8 for placebo, translating to 2.6 extra cases per 100,000 users.
Real-world evidence
Studies tracking 600,000 veterans found 390 NAION cases per 100,000 on GLP-1 drugs versus 290 on alternative medications.
European regulators
European regulators found semaglutide carries a very rare NAION risk, requiring updated package inserts for this side effect.
Patient advice

Patients should seek immediate care for vision problems and discuss risks with doctors, especially those with diabetes, high blood pressure, or sleep apnea.
Risk summary
The risk of NAION with GLP-1 drugs is small but real, with 2.6 extra cases per 100,000 users, not a cause for alarm.
The key point
FDA adds NAION risk to GLP-1 drug warnings after studies show 2.6 extra cases per 100,000 users.
Read the TL;DR — this story on one card.





